Drug Profile
Losmapimod - Fulcrum Therapeutics
Alternative Names: 856553; FTX-1821; GS856553; GSK 856553; GW 856553; GW856553XLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Fulcrum Therapeutics; GlaxoSmithKline; GSK
- Class Amides; Analgesics; Anti-inflammatories; Antidepressants; Antihyperlipidaemics; Antirheumatics; Antivirals; Cardiovascular therapies; Cyclopropanes; Fluorobenzenes; Pyridines; Small molecules; Vascular disorder therapies
- Mechanism of Action DUX4 protein inhibitors; P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute coronary syndromes; COVID 2019 infections; Facioscapulohumeral muscular dystrophy
- Phase II Chronic obstructive pulmonary disease; Focal segmental glomerulosclerosis
- No development reported Inflammation
- Discontinued Atherosclerosis; Dyslipidaemias; Major depressive disorder; Neuropathic pain; Rheumatoid arthritis
Most Recent Events
- 07 Sep 2023 Fulcrum Therapeutics completes enrolment in the phase III REACH trial for Facioscapulohumeral muscular dystrophy in USA, Canada and Europe (PO)
- 22 Apr 2023 Efficacy and safety data from a phase IIb ReDUX4 trial in Facioscapulohumeral muscular dystrophy was presented at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)
- 22 Apr 2023 Efficacy data from a phase II trial in Facioscapulohumeral muscular dystrophy presented at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)